Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
58.36
+0.38 (0.66%)
Aug 11, 2026, 11:42 AM EDT - Market open
Royalty Pharma Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 33,554 | 16,564 | 11,377 | 12,548 | 17,514 | 17,254 | |
Market Cap Growth | 55.00% | 45.59% | -9.33% | -28.36% | 1.51% | -11.18% |
Enterprise Value | 41,679 | 28,134 | 21,456 | 21,764 | 26,792 | 26,699 |
Last Close Price | 58.36 | 38.64 | 25.51 | 28.09 | 39.52 | 39.85 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 31.09 | 21.71 | 13.36 | 11.10 | 395.20 | 26.75 |
Forward PE | 10.75 | 7.70 | 6.10 | 7.47 | 10.32 | 13.00 |
PEG Ratio | 1.34 | 0.79 | 2.14 | 2.65 | 0.94 | 1.12 |
PS Ratio | 13.21 | 6.96 | 5.03 | 5.33 | 7.83 | 7.54 |
PB Ratio | 3.78 | 2.56 | 1.64 | 1.92 | 3.11 | 2.99 |
P/TBV Ratio | 5.50 | 3.93 | 2.18 | 2.60 | 3.08 | 2.86 |
P/FCF Ratio | 11.26 | 6.65 | 4.11 | 4.20 | 8.17 | 8.55 |
P/OCF Ratio | 11.26 | 6.65 | 4.11 | 4.20 | 8.17 | 8.55 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 16.42 | 11.83 | 9.48 | 9.24 | 11.98 | 11.66 |
EV/EBITDA Ratio | 27.45 | 18.00 | 16.60 | 14.59 | 87.25 | 18.66 |
EV/EBIT Ratio | 27.54 | 18.04 | 16.60 | 14.59 | 87.25 | 18.66 |
EV/FCF Ratio | 13.99 | 11.30 | 7.75 | 7.28 | 12.50 | 13.23 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.88 | 0.88 | 0.64 | 0.61 | 0.64 | 0.69 |
Debt / EBITDA Ratio | 5.91 | 5.73 | 5.89 | 4.11 | 23.18 | 4.96 |
Debt / FCF Ratio | 3.01 | 3.60 | 2.75 | 2.05 | 3.32 | 3.52 |
Net Debt / Equity Ratio | 1.19 | 1.29 | 0.96 | 0.87 | 0.96 | 0.86 |
Net Debt / EBITDA Ratio | 5.37 | 5.33 | 5.17 | 3.79 | 17.52 | 3.48 |
Net Debt / FCF Ratio | 2.74 | 3.35 | 2.41 | 1.89 | 2.51 | 2.47 |
Asset Turnover | 0.13 | 0.13 | 0.13 | 0.14 | 0.13 | 0.14 |
Quick Ratio | 1.34 | 1.02 | 0.76 | 3.09 | 1.52 | 12.80 |
Current Ratio | 2.80 | 2.40 | 1.44 | 7.90 | 2.19 | 16.81 |
Return on Equity (ROE) | 13.84% | 13.20% | 13.03% | 17.34% | 2.33% | 12.32% |
Return on Assets (ROA) | 7.67% | 8.24% | 7.47% | 8.99% | 1.79% | 8.53% |
Return on Invested Capital (ROIC) | 8.06% | 8.62% | 7.79% | 9.63% | 2.02% | 9.89% |
Return on Capital Employed (ROCE) | 7.92% | 8.68% | 7.79% | 9.36% | 1.86% | 8.66% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.42% | 4.61% | 7.49% | 9.01% | 0.25% | 3.74% |
FCF Yield | 8.88% | 15.03% | 24.34% | 23.81% | 12.24% | 11.69% |
Dividend Yield | 1.62% | 2.28% | 3.29% | 2.85% | 1.93% | 1.73% |
Payout Ratio | 50.42% | 49.06% | 43.83% | 31.58% | 778.21% | 46.02% |
Buyback Yield / Dilution | 3.88% | 4.99% | 1.46% | -37.66% | -5.59% | -10.48% |
Total Shareholder Return | 5.50% | 7.27% | 4.75% | -34.81% | -3.66% | -8.75% |